

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINOPHARM GROUP CO. LTD.*
國藥控股股份有限公司

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock code: 01099)

SUPPLEMENTAL NOTICE OF EGM

Reference is made to the notice of the extraordinary general meeting (the “**EGM**”) of Sinopharm Group Co. Ltd. (the “**Company**”) dated 1 September 2016 (the “**Notice**”) which sets out the time and venue of the EGM and contains the resolution to be proposed at the EGM for shareholders’ approval.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the EGM will be held as originally scheduled at Meeting Room 1813, Sinopharm Plaza, No. 1001 Zhongshan West Road, Changning District, Shanghai, the People’s Republic of China (the “**PRC**”) at 9:00 a.m. on Tuesday, 18 October 2016 for the purpose of considering, and if thought fit, passing the following resolution in addition to the resolution set out in the Notice:

ORDINARY RESOLUTION

2. To consider and, if thought fit, to approve the appointment of Mr. Ma Ping as a non-executive director of the Company (the “**Director(s)**”), to authorise the board of directors of the Company (the “**Board**”) to determine his remuneration, and to authorise any executive Director to execute a service contract or such other documents or supplemental agreements or deeds on behalf of the Company.

By Order of the Board of
Sinopharm Group Co. Ltd.
Wei Yulin
Chairman

Shanghai, the PRC
30 September 2016

* *The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”*

As at the date of this notice, the executive directors of the Company are Mr. Wei Yulin and Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Li Yuhua, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong, and Mr. Wu Yijian; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

Notes:

1. Details of the above resolution are set out in the appendix of this supplemental notice of EGM (the “**Supplemental Notice**”).
2. A supplemental proxy form is enclosed with this Supplemental Notice.
3. Please refer to the Company’s circular dated 1 September 2016 and the Notice for details of the other resolution to be proposed at the EGM, eligibility for attending the EGM, appointment of proxy, registration procedures, closure of register of members and other relevant matters.

APPENDIX – BIOGRAPHICAL DETAILS OF MR. MA PING

Mr. Ma Ping, aged 60, has over 34 years of working experience and currently serves as an external director of China National Pharmaceutical Group Corporation. Mr. Ma served as principal clerk, engineer, vice director and director of Ministry of Labor and Personnel, National Pharmaceutical Administration, State Planning Commission, respectively from February 1982 to March 1992. He served as department manager, project manager, general manager of London Export Corporation, Hoechst (China), Lotus Healthcare, respectively from March 1992 to April 1994. He co-founded and served as managing director of BMP from April 1994 to October 1996. He served as investment director, business development director of Sinogen International Ltd. from October 1996 to May 1998. He served as vice president, COO, China general manager of United Medical Industrial Group from May 1998 to March 2000. He served as director, vice general manager of Tonghua Goldenhorse Group (a Shenzhen Stock Exchange-listed company, stock code: 000766) from March 2000 to September 2001. He served as director, general manager of BMP (a Nasdaq-listed company, stock code: BJGP) from September 2001 to December 2005. He served as director, general manager of BioPro Pharmaceutical Inc. from December 2005 to December 2011. He has been serving as director of BioPro Pharmaceutical Inc. and project consultant of Principle Capital since December 2011, and has been serving as an external director of China National Pharmaceutical Group Corporation since May 2016. Mr. Ma received a bachelor degree from chemistry department of Fudan University in 1982.

Save as disclosed above and as at the date of this notice, Mr. Ma does not have any relationships with any Directors, senior management, substantial or controlling shareholder(s) of the Company, or holds any other positions in the Company or any of its subsidiaries, or any directorships in other listed companies in the last three years.

As at the date of this notice, Mr. Ma does not have any interest in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Upon due appointment as a non-executive Director, Mr. Ma will enter into a service contract with the Company for a term commencing from the date of appointment and ending on the expiration of the term of the current session of the Board. Pursuant to the articles of association of the Company, Mr. Ma will be subject to retirement by rotation and re-election upon the expiry of his term of office.

Mr. Ma's remuneration package will be determined by the Board as authorized by the shareholders of the Company at a general meeting of the Company by taking into account, among other matters, his terms of reference, his duties and responsibilities in the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to Mr. Ma's appointment as a non-executive Director that need to be brought to the attention of the shareholders of the Company nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.